Aptahem attends the BioStock Investor Meeting on 20 September 2023


Aptahem’s CEO Mikael Lindstam is presenting the company and gives an update on the ongoing activities. The presentation, which is held in English, can be followed at the physical event in Stockholm on 20 September at 15.00 CET.

More information about the event and link to registration page is available on the BioStock website.

For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem
Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.